FDA-APPROVED TREATMENT TO GROW EYELASHES FOR PEOPLE WITH INADEQUATE OR NOT ENOUGH LASHES.

Latisse® in Kansas City & Overland Park

(bimatoprost ophthalmic solution) 0.03% Important Information

Request a Consultation

LATISSE®

Before and After

LATISSE® (BIMATOPROST OPHTHALMIC SOLUTION) 0.03%

Helps you grow lashes longer, fuller, and darker in just 16 weeks. Contact us to see if LATISSE® solution is right for you.

REQUEST A CONSULTATION

WHAT HAPPENS IF I STOP USING LATISSE®?

If you stop using LATISSE®, your eyelashes are expected to return to their previous appearance over several weeks to months. Any eyelid skin darkening is expected to reverse after several weeks to months. Any darkening of the colored part of the eye known as the iris is NOT expected to reverse and is likely permanent.

REQUEST A CONSULTATION

HOW DO I USE LATISSE®?

The recommended dosage is one application nightly to the skin of the upper eyelid margin at the base of the eyelashes only. Once nightly, start by ensuring your face is clean, makeup and contact lenses are removed. Remove an applicator from its tray. Then, holding the sterile applicator horizontally, place one drop of LATISSE® on the area of the applicator closest to the tip but not on the tip (see Illustration 1). Then immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part (see Illustration 2). Blot any excess solution beyond the eyelid margin. Dispose of the applicator after one use. Repeat for the opposite upper eyelid margin using a new sterile applicator. This helps minimize any potential for contamination from one eyelid to another.

UPNEEQ ^®

(oxymetazoline hydrochloride ophthalmic solution), 0.1%

Low-lying lids may be caused by acquired blepharoptosis.

If you see signs of low-lying lids, talk to your RSVP Esthetician about getting UPLIFTED with Upneeq!

PRODUCT INFORMATION

Warnings And Precautions
- Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
- Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
- Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
Adverse Reactions

Lorem ipsum dolor sit amet consectetur adipisicing elit. Necessitatibus, odit.

General Information about LATISSE® Prescription treatments are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LATISSE® solution for a condition for which it was not prescribed. Do not give LATISSE® to other people. It may not be appropriate for them to use. This leaflet summarizes the most important information about LATISSE® solution. If you would like more information, talk with your physician. You can also call Allergan’s product information department at 1-800- 678-1605. What are the ingredients in LATISSE®?

Active ingredient: bimatoprost Inactive ingredients: benzalkonium chloride; sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 – 7.8.